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 Image of patient’s octreotide scan: positive 
findings in right lower quadrant 
 
 
 
 
2.4X2.7X3cm carcinoid tumor at the ileocecal 
junction seen on IV contrast CT scan 
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INTRODUCTION 
 
Resection of carcinoid tumors 
have significant implications for 
anesthetic management due to 
concern for intraoperative 
hemodynamic changes of 
hypotension or hypertension 
and bronchospasm.  Octreotide 
has now become the mainstay 
of therapy for carcinoid tumor 
resection.  Below we present a 
case of carcinoid tumor 
resection with the use of 
octreotide, in addition to other 
agents, to prevent and treat 
intraoperative complications. 
 
CASE DESCRIPTION  
 
A 58 year old male with 
asymptomatic carcinoid tumor 
of the bowel, diagnosed with  
positive octreotide scan, 
presented for resection of the 
tumor from the ileocecal 
junction.  The patient was given 
steroids and histamine blockers 
prior to induction and an 
octreotide infusion was begun.  
The patient was induced and 
intubated and blood pressure 
was monitored perioperatively 
with radial arterial line.  
Hypotension with systolic blood 
pressures less than 80mmHg 
occurred with tumor 
manipulation and was 
successfully treated with 
octreotide and phenylephrine.  
At the case’s end, the octreotide 
infusion was discontinued and 
the patient was extubated and 
taken to PACU in stable 
condition.  
DISCUSSION 
 
Carcinoid Tumors 
 
• Occur in only 0.2-10/100,000 people, incidental  findings on autopsies 
 show rates as high as 8%.1 
• Develop from neuroendocrine cells and secrete a variety of 
   neuropeptides and vasoactive substances, including: serotonin,  
   bradykinin, vasoactive intestinal polypeptide, kallikrein, substance P 
   and histamine.2   
• 75% occur in the GI tract, location of origin correlates with the type of  
   substance released.  Signs and symptoms  include flushing, diarrhea,  
  bronchospasm, hypertension, hypotension and hyperglycemia.3  
 
Intraoperative Management 
 
• An arterial line should be placed to  monitor  significant  
hemodynamic   changes caused by peptide release. These changes   
     can  be precipitated   by anxiety and catecholamine release during   
     induction.  Peptide release can also be  precipitated by   
     hypercapnea,  hypotension or hypothermia.3 
• To ensure a smooth induction, avoid medications that cause the 
     release of histamines. Certain non-depolarizing muscle relaxants, 
     succinylcholine and morphine should be avoided to prevent  
     precipitation of bronchospasm. 
• Avoid beta and alpha adrenergic agonists as these can precipitate  
  release of peptides.  
• Today’s main line of prevention and treatment of symptoms from 
   peptide release is octreotide, a synthetic somatostatin analog with a 
   longer half life that prevents hormone release, blocks the actions of 
   released peptides, and inhibits insulin secretion.1   
 
Perioperatively 
 
• Octreotide can be infused at a rate of 50-100mcg/hr, and boluses of  
   25-100mcg can be given2 for hypotension, hypertension and 
   bronchospasm with effects seen in about 10 minutes.   
• Circulating peptides can still cause symptoms even after tumor 
   resection, and octreotide may need to be continued  postoperatively.  
CONCLUSION 
 
Octreotide infusion is the mainstay therapy for intraoperative prevention 
and management of hemodynamic instability and bronchospasm.  Other 
agents such as antihistamines and steroids may also be used, while 
histamine-releasing agents and adrenergic agonists should be avoided.  
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